Ki Y. Chung

8.1k total citations · 1 hit paper
62 papers, 2.4k citations indexed

About

Ki Y. Chung is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Ki Y. Chung has authored 62 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 10 papers in Surgery. Recurrent topics in Ki Y. Chung's work include Colorectal Cancer Treatments and Studies (17 papers), Pancreatic and Hepatic Oncology Research (9 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Ki Y. Chung is often cited by papers focused on Colorectal Cancer Treatments and Studies (17 papers), Pancreatic and Hepatic Oncology Research (9 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Ki Y. Chung collaborates with scholars based in United States, United Kingdom and Germany. Ki Y. Chung's co-authors include Leonard B. Saltz, Deborah Schrag, Jinru Shia, David S. Klimstra, Manish A. Shah, David P. Kelsen, Nancy E. Kemeny, Daniel Fridman, Archie Tse and Lawrence B. Schwartz and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Ki Y. Chung

61 papers receiving 2.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry

2005 848 citations Ki Y. Chung, Deborah Schrag et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Ki Y. Chung	1.6k	702	617	324	267	62	2.4k
G. Deplanque	1.3k 0.8×	812 1.2×	633 1.0×	166 0.5×	225 0.8×	77	2.3k
Elena De Mattia	963 0.6×	324 0.5×	725 1.2×	200 0.6×	198 0.7×	92	2.0k
Dusan Kotasek	1.2k 0.7×	542 0.8×	448 0.7×	371 1.1×	183 0.7×	104	2.3k
Denis L. Jardim	1.1k 0.6×	671 1.0×	625 1.0×	248 0.8×	203 0.8×	63	2.0k
Francesca Bergamo	1.8k 1.1×	693 1.0×	429 0.7×	577 1.8×	522 2.0×	211	2.5k
Holger W. Hirte	978 0.6×	430 0.6×	763 1.2×	160 0.5×	216 0.8×	46	2.0k
Nobuyuki Mizunuma	1.5k 0.9×	530 0.8×	506 0.8×	231 0.7×	259 1.0×	133	2.0k
Jane Robertson	1.3k 0.8×	510 0.7×	816 1.3×	176 0.5×	92 0.3×	57	2.0k
Randeep Sangha	1.3k 0.8×	542 0.8×	590 1.0×	490 1.5×	376 1.4×	72	2.3k
Virote Sriuranpong	1.1k 0.7×	381 0.5×	995 1.6×	220 0.7×	205 0.8×	77	2.2k

Countries citing papers authored by Ki Y. Chung

Since Specialization

Citations

This map shows the geographic impact of Ki Y. Chung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ki Y. Chung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ki Y. Chung more than expected).

Fields of papers citing papers by Ki Y. Chung

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ki Y. Chung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ki Y. Chung. The network helps show where Ki Y. Chung may publish in the future.

Co-authorship network of co-authors of Ki Y. Chung

This figure shows the co-authorship network connecting the top 25 collaborators of Ki Y. Chung. A scholar is included among the top collaborators of Ki Y. Chung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ki Y. Chung. Ki Y. Chung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hecht, J. Randolph, Jean‐Marie Michot, David J. Bajor, et al.. (2025). CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours. PubMed. 3(1). 10–10. 1 indexed citations

Day, Daphne, Vinod Ganju, Ki Y. Chung, et al.. (2025). First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors. British Journal of Cancer. 132(10). 905–912. 3 indexed citations

Salem, Mohamed E., Shannon L. Puhalla, Thomas J. George, et al.. (2024). NSABP C-14/Exact Sciences 16-002: CORRECT-MRD II—Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease.. Journal of Clinical Oncology. 42(3_suppl).

Day, Daphne, Vinod Ganju, Ki Y. Chung, et al.. (2023). 1028P Preliminary phase I results from a first-in-human study of EMB-02, a PD-1xLAG-3 bispecific antibody, in patients (pts) with advanced solid tumors. Annals of Oncology. 34. S625–S625. 4 indexed citations

Goodman, Karyn A., Michael J. Pishvaian, Charles D. Lopez, et al.. (2023). Toxicity and efficacy of stereotactic body radiation therapy vs. intensity-modulated radiation therapy for the treatment of locally advanced pancreatic cancer in a phase 3 trial.. Journal of Clinical Oncology. 41(4_suppl). 713–713. 1 indexed citations

Pishvaian, Michael J., Amer H. Zureikat, Charles D. Lopez, et al.. (2023). Abstract CT084: Targeted intra-arterial gemcitabine vs. continuation of IV gemcitabine plus nab-paclitaxel following Induction with sequential IV gemcitabine plus nab-paclitaxel and radiotherapy for unresectable locally advanced pancreatic cancer (TIGeR-PaC) - phase III trial interim analysis. Cancer Research. 83(8_Supplement). CT084–CT084. 1 indexed citations

Pishvaian, Michael J., Charles D. Lopez, Emmanuel E. Zervos, et al.. (2023). LBA-1 The Phase III Study: Targeted intra-arterial gemcitabine vs. continuation of IV gemcitabine plus nab-paclitaxel following induction with sequential IV gemcitabine plus nab-paclitaxel and radiotherapy for locally advanced pancreatic cancer (TIGeR-PaC). Annals of Oncology. 34. S178–S178. 1 indexed citations

Zhou, Xiaofei, Ulka N. Vaishampayan, Devalingam Mahalingam, et al.. (2022). Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. Investigational New Drugs. 40(5). 1042–1050. 7 indexed citations

Saleh, Mansoor N., Manish R. Patel, Todd M. Bauer, et al.. (2021). Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53. Clinical Cancer Research. 27(19). 5236–5247. 110 indexed citations

10.

Plummer, Ruth, Emma Dean, Hendrik‐Tobias Arkenau, et al.. (2021). A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer. Lung Cancer. 163. 19–26. 26 indexed citations

11.

Chung, Ki Y., et al.. (2011). Phase I Study of Two Schedules of Oral S-1 in Combination with Fixed Doses of Oxaliplatin and Bevacizumab in Patients with Advanced Solid Tumors. Oncology. 81(2). 65–72. 4 indexed citations

12.

Jesus‐Acosta, Ana De, George R. Oliver, Amanda L. Blackford, et al.. (2011). A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology. 69(2). 415–424. 29 indexed citations

13.

Choi, Hyun Seok, et al.. (2010). Ultrasonographic finding of internal jugular vein during anti-G straining maneuver: is it associated with gravity-induced loss of consciousness?. European Journal of Applied Physiology. 109(4). 625–630. 3 indexed citations

14.

Shah, Manisha H., Kimberly A. Varker, Minden Collamore, et al.. (2009). G3139 (Genasense) in Patients With Advanced Merkel Cell Carcinoma. American Journal of Clinical Oncology. 32(2). 174–179. 34 indexed citations

15.

Moore, Malcolm A.S., Ki Y. Chung, Magdalena Plašilová, et al.. (2007). NUP98 Dysregulation in Myeloid Leukemogenesis. Annals of the New York Academy of Sciences. 1106(1). 114–142. 46 indexed citations

16.

Chung, Ki Y. & Leonard B. Saltz. (2007). Adjuvant Therapy of Colon Cancer: Current Status and Future Directions. The Cancer Journal. 13(3). 192–197. 65 indexed citations

17.

Moore, Malcolm A.S., David C. Dorn, Jan Jacob Schuringa, Ki Y. Chung, & Giovanni Morrone. (2007). Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells. Experimental Hematology. 35(4). 105–116. 43 indexed citations

18.

Chung, Ki Y., Giovanni Morrone, Jan Jacob Schuringa, et al.. (2006). Enforced Expression of NUP98-HOXA9 in Human CD34+ Cells Enhances Stem Cell Proliferation. Cancer Research. 66(24). 11781–11791. 57 indexed citations

19.

Schrag, Deborah, Ki Y. Chung, Carlos D. Flombaum, & Leonard B. Saltz. (2005). Cetuximab Therapy and Symptomatic Hypomagnesemia. JNCI Journal of the National Cancer Institute. 97(16). 1221–1224. 175 indexed citations

20.

Lee, Ik Jae, et al.. (1995). Hypereosinophilic syndrome on the extremities associated with abnormal peripheral blood circulation. Linchuang pifuke zazhi. 33(1). 104–108. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact